LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

The Ensign Group Increases Quarterly Dividend to $0.0575 Per Share

December 16, 2022 | Last Trade: US$143.49 2.19 -1.50

SAN JUAN CAPISTRANO, California, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0575 per share of Ensign common stock, payable on or before January 31, 2023, to shareholders of record as of December 31, 2022. “We are pleased to announce our twentieth consecutive annual dividend increase, which reflects our strong market position and continued commitment to return value to our shareholders,” commented Barry Port, Ensign's Chief Executive Officer. “We look forward to continued growth and are optimistic about our long-term prospects,” he added.

Ensign has been a dividend-paying company since 2002.

About Ensign

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 271 healthcare facilities, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it.


Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB